FDA Declares Tirzepatide Shortage Resolved, Tightening Rules on Compounded Copies
Monday, June 15th, 2026 - The U.S. Food and Drug Administration has determined that the nationwide shortage of tirzepatide injection, a dual GIP/GLP-1 drug marketed for type 2 diabetes and weight management, is over. The decision, announced in a CDER update, triggers stricter limits on compounding pharmacies that have been producing unapproved copies of the drug since 2022.
Compounding pharmacies face a narrower path
The FDA's shortage resolution means that compounding pharmacies operating under section 503A and outsourcing facilities under section 503B can no longer rely on the shortage exception to make large quantities of tirzepatide. The agency's compounding inspections, recalls, and other actions page tracks ongoing enforcement. The Alliance for Pharmacy Compounding and the Outsourcing Facilities Association have not yet issued public statements on the change.
The National Association of Boards of Pharmacy continues to monitor state-level enforcement, according to its newsroom. The FDA's warning letter database remains a resource for tracking compliance actions against compounders.
Pipeline records keep retatrutide in focus
Clinical trial records on ClinicalTrials.gov show ongoing studies for retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors. Peer-reviewed literature in the New England Journal of Medicine and Nature continues to publish data on incretin-based therapies. Company announcements from Eli Lilly and Novo Nordisk indicate active development programs, though neither has filed for retatrutide approval.
Sports rules remain separate
The World Anti-Doping Agency's prohibited list includes peptide hormones, growth factors, and related substances. Athletes should verify current WADA rules before using any peptide-based medication, as the classification does not automatically cover all GLP-1 drugs.
